Fritextsökning
Artiklar per år
Innehållstyper
-
A billion-dollar acquisition makes Novo Nordisk even bigger in obesity
Danish pharmaceutical giant Novo Nordisk acquires Montreal-based Inversago Pharma, which develops treatments for obesity and diabetes.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded the winners and punished the losers”. Here is the background of the story which has shaken the American scientific community over the summer.
-
Uppsala-based company wins important patent dispute – but the decision is subject to appeal
A US district court has ruled in favour of Orexo in a dispute over the patent protecting the Swedish company’s drug Zubsolv, developed for treating patients with opioid addiction. However, the opposing party, the Indian company Sun, is not giving up and has filed an appeal.
-
Förlikning i babypuderskandal stoppas av domstol
Det amerikanska läkemedelsbolaget Johnson & Johnson har för en andra gång fått avslag av en domare om en konkursansökan för dotterbolaget LTL Management, mest känt som enheten bakom det omtalade babypudret som misstänkts ha orsakat cancer i en rad fall.
-
The Swedish Life Science Office: “We lost in both coordination and manpower”
Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Departmental Secretary at the office, about the ongoing work.
-
Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?
In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.
-
Anna Törner: The minute between life and death
“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try to understand why I haven’t told anyone, I find the answer: a feeling of shame
-
Nanexa develops depot formulation of the diabetes and obesity drug Saxenda
Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The drug is currently approved for the treatment of diabetes and obesity.
-
Study: Semaglutide tablet produces weight loss
The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.
-
Egetis lägger ned buddiskussionerna
Svenska läkemedelsutvecklaren Egetis Therapeutics har gått ut med att diskussionerna om ett potentiellt förvärv av företaget nu har lagts ner.
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, writes Samuel Lagercrantz in an editorial.
-
Swedish and Ukrainian Medical Product Agencies sign an agreement
The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.
-
The first Lyme disease vaccine faces a delay
Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the United States, which have forced the companies to drop half of the participants in an ongoing
-
A new malaria vaccine offers hope but much more research is still needed
There has long been no vaccine against malaria, but there have been breakthroughs in recent years. However, it is still unclear how we become immune to the malaria parasite, and this is a vital piece of the puzzle for creating effective vaccines, says malaria researcher Kristina Persson.
-
Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”
How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cluster organisation’s new radar pair.
-
New report: Fewer PhDs in life sciences
A new report from Vinnova suggests that competency returns in the life science sector are declining.
-
Uncertainty about the government’s life science work
The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now questions are being raised both about the government’s plans for the office and the Swedish life
-
He got inside the head of Sweden’s vaccine hunter
The hunt for the COVID-19 vaccine is the theme of the new book Vaccinjägaren (The Vaccine Hunter). It tells the story of Richard Bergström’s mission as Sweden’s national vaccine coordinator and the scheming that went on behind the scenes in Europe
-
New diagnostic rules raise concerns
In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagnostics (IVDR). They argue that it may create significant differences between regions
-
New drug alert in the US: Rise in overdoses linked to the use of drugs for animals
A combination of the synthetic drugs fentanyl and xylazine, an animal tranquilizer, has been labelled a “growing threat” by the White House due to its role in the ongoing opioid crisis in the US.
-
Elypta awarded one million USD from the Star Trek creator’s foundation
Swedish company Elypta, which develops methods for early cancer detection, has been awarded one million USD from an unexpected source: a foundation set up in memory of the creator of Star Trek.
-
Conference on Alzheimer’s reveals several advances in the field
In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Science Sweden has talked to some of those that attended the conference.
-
The impact of the recession on the Swedish medtech sector
We need health care regardless of whether the economy is good or bad, but the current recession also affects the Medtech sector.
-
He will be the new chair of Medicon Valley Alliance
Niels Abel Bonde is the nomination committee’s proposal and the most likely person to take over as the new chairman of the Swedish-Danish life science cluster organisation Medicon Valley Alliance (MVA).
BREAKING